Hepatic Disease Mechanisms and Therapeutic Interventions

The liver is central to nutrient metabolism, detoxification and immune surveillance. Disruption of hepatic lipid handling, chronic inflammation and aberrant extracellular matrix deposition underlie a spectrum of conditions ranging from nonalcoholic fatty liver disease to steatohepatitis, fibrosis and cirrhosis. At the cellular level, excessive uptake or synthesis of fatty acids leads to lipid droplet accumulation in hepatocytes, triggering oxidative stress, endoplasmic reticulum stress and activation of resident macrophages (Kupffer cells). Inflammasome assembly and pro-inflammatory cytokine release amplify injury, while activation of hepatic stellate cells drives fibrogenesis through collagen deposition and tissue remodelling. Epigenetic alterations further modulate gene expression programmes that sustain pathology. Therapeutic strategies under investigation include modulation of key metabolic sensors (for example AMPK), inhibition of inflammatory cascades (such as NF-κB and NLRP3 inflammasome), restoration of redox balance, targeting of profibrotic signalling (TGF-β/SMAD) and harnessing intercellular vesicles to deliver regulatory RNAs. In addition, small molecules and natural products with antioxidant, lipid-lowering or anti-fibrotic properties have shown promise in preclinical models. A comprehensive approach that integrates lifestyle intervention with precision pharmacology is essential to curb the global burden of liver disease and its complications.

Research from Nature Portfolio

Studies in metabolic disease models have demonstrated the efficacy of agents that enhance fatty acid β-oxidation to reverse steatosis. One foundational investigation revealed that administration of pentoxifylline in hyperglycaemic, dyslipidaemic mice restored impaired β-oxidation pathways, attenuated lipid accumulation and improved liver histology. This work elucidated how modulation of energy‐homeostasis pathways can counteract steatotic injury. Another seminal report employed lipidomic profiling to evaluate the bioactive compound Schisandrin B in high-fat-fed mice. Treatment reduced hepatic palmitic acid synthesis, suppressed profibrotic markers and activated antioxidant responses through the Nrf2 axis, collectively diminishing inflammation and collagen deposition. These studies highlight how targeted perturbation of lipid biosynthesis and oxidative stress pathways can yield durable benefits in experimental steatohepatitis and fibrosis.

Hepatic Disease Mechanisms and Therapeutic Interventions publication trend

The graph below shows the total number of articles in hepatic disease mechanisms and therapeutic interventions across all publications each year (not limited to Nature Index journals).

Technical terms

Nonalcoholic fatty liver disease (NAFLD): accumulation of lipid within hepatocytes in the absence of significant alcohol consumption.

Hepatic steatosis: excessive deposition of triglyceride droplets in liver cells.

Inflammasome: cytosolic multi-protein complex that activates pro-inflammatory cytokines such as IL-1β.

Exosome: nano-scale extracellular vesicle secreted by cells to transfer proteins, lipids and nucleic acids.

Epigenetic modification: heritable alteration of gene expression without changes to the DNA sequence, often via histone marks or DNA methylation.

Epithelial–mesenchymal transition (EMT): process whereby epithelial cells adopt a mesenchymal phenotype, facilitating migration and fibrotic remodelling.

References

1. Pentoxifylline ameliorates non-alcoholic fatty liver disease in hyperglycaemic and dyslipidaemic mice by upregulating fatty acid β-oxidation. Scientific Reports (2016).
2. Lipidomic-based investigation into the regulatory effect of Schisandrin B on palmitic acid level in non-alcoholic steatotic livers. Scientific Reports (2015).
3. Genome‐Wide Profiling of H3K27ac Identifies TDO2 as a Pivotal Therapeutic Target in Metabolic Associated Steatohepatitis Liver Disease. Advanced Science (2024).
4. Hepatocyte-derived exosomal miR-146a-5p inhibits hepatic stellate cell EMT process: a crosstalk between hepatocytes and hepatic stellate cells. Cell Death Discovery (2023).
5. Puerarin ameliorates nonalcoholic fatty liver in rats by regulating hepatic lipid accumulation, oxidative stress, and inflammation. Frontiers in Immunology (2022).